The excitement around Moderna's cancer vaccine is cooling. Here's why.
Merck & Co Inc MRK
News
Moderna's cancer vaccine is 'likely' to get approved. Skeptics question if it will be the best option.
Moderna's cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
Moderna has a plan to revolutionize how certain cancers are treated. We're about to find out its potential in melanoma.
7 healthcare stocks that stand out as investors pay up for the sector
7 healthcare stocks that stand out as -2-
Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets
Formycon Shares Jump After FDA Accepts Application for Keytruda Biosimilar
Halozyme Wins Injunction Against Merck in Keytruda Patent Case — Update
Halozyme Granted Another Injunction Against Merck in Keytruda Patent Case
Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug
Vaxcyte Reports Bacterial-Infection Vaccine Met Primary Endpoints in Phase 3 Trial
Citi tells investors it's time to sell Moderna after 600%-plus stock gains
Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics — Update
Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics
Merck, Daiichi Sankyo Withdraw Application for Accelerated Approval of Lung Cancer Treatment
Merck, Eisai Get FDA OK of Welireg/Lenvima Combo in Kidney Cancer
Merck Phase 2b/3 Trial for Remigromig Meets Primary Endpoint
Moderna will reveal the data for its mRNA cancer vaccine next month. Here's why it matters.
Moderna's personalized mRNA shot could reshape the fight against skin cancer - but it may also be overhyped
United States